Hepatitis B virus reactivation in hepatitis B surface antigen seropositive patients with metastatic non-small cell lung cancer receiving cytotoxic chemotherapy: The efficacy of preemptive lamivudine and identification of risk factors

Medical Oncology

Volumn 31, Issue 8, 2014, Pages

  Lin, Gui Nan ^a   Peng, Jie Wen ^a   Xiao, Jian Jun ^a   Liu, Dong Ying ^a   Xia, Zhong Jun ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Chemotherapy; Hepatitis B virus; Lamivudine; Non small cell lung cancer; Reactivation

Indexed keywords

ANTINEOPLASTIC AGENT; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS REACTIVATION; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CONTROLLED CLINICAL TRIAL; DRUG EFFECTS; GENETICS; LIVER NEOPLASMS; MIDDLE AGED; PATHOGENICITY; PATHOLOGY; RISK FACTOR; VIROLOGY; VIRUS ACTIVATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84905447670     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0119-0     Document Type: Article

References (28)

1. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45(2):507-39. (Pubitemid 46374607)
2. Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49(S5):S156-65.
3. Xunrong L, Yan AW, Liang R, Lau GK. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy - pathogenesis and management. Rev Med Virol. 2001;11(5):287-99. (Pubitemid 33009970)
4. Ozguroglu M, Bilici A, Turna H, Serdengecti S. Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma. Med Oncol. 2004;21(1):67-72. (Pubitemid 38491332)
5. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661-2.
6. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92-8. (Pubitemid 34438899)
7. Lilenbaum RC, Herndon JE 2nd, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2005;23(1):190-6. (Pubitemid 41702638)
8. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43(2):209-20.
9. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97-107. (Pubitemid 38365759)
10. Horvath J, Raffanti SP. Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. Clin Infect Dis. 1994;18(3):339-47. (Pubitemid 24086302)
11. Mondelli M, Vergani GM, Alberti A, et al. Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol. 1982;129(6):2773-8. (Pubitemid 13245559)
12. Lau GK, Liang R, Chiu EK, Lee CK, Lam SK. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplant. 1997;19(8):795-9. (Pubitemid 27207895)
13. Chen XQ, Peng JW, Lin GN, Li M, Xia ZJ. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. Med Oncol. 2012;29(2):1237-41.
14. Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int. 2004;24(6):540-6. (Pubitemid 40028604)
15. Yeo W, Hui EP, Chan AT, et al. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol. 2005;28(4):379-84. (Pubitemid 41099543)
16. Huang H, Cai Q, Lin T, et al. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience. Expert Opin Pharmacother. 2009;10(15):2399-406.
17. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148(7):519-28. (Pubitemid 351665421)
18. Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology. 2008;47(3):844-53. (Pubitemid 351449676)
19. Eren OO, Artac M, Boruban MC, Yavas O, Arslan U, Basaranoglu M. Chemotherapy-induced hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience. Med Oncol. 2009;26(4):386-92.
20. Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica. 2009;94(7):998-1005.
21. Shikata T, Karasawa T, Abe K, et al. Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis. 1977;136(4):571-6. (Pubitemid 8211390)
22. Jang JW, Choi JY, Bae SH, et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol. 2004;41(3):427-35. (Pubitemid 39158752)
23. Lau GK, Leung YH, Fong DY, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002;99(7):2324-30. (Pubitemid 34525416)
24. Zhong S, Yeo W, Schroder C, Chan P, Wong W, Ho WM, et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat. 2004;11(1):55-9. (Pubitemid 38221618)
25. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62(3):299-307.
26. Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004;22(5):927-34. (Pubitemid 41103605)
27. Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int. 2008;2(2):152-62. (Pubitemid 351650143)
28. Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol. 2014;11(4):209-19.